<DOC>
	<DOCNO>NCT02413099</DOCNO>
	<brief_summary>Background : KBMSI-2 , herbal formular consist Ginseng Radix Rubra , Dioscorea tenuipes , Cornus officinalis Sieb . Et Zucc , Lycium Chinese Mill , Curcuma logna Linn , Honey , improve erectile function preserve smooth muscle content inhibit fibrosis corpus cavernosum STZ-induced diabetic rat model . In study , researcher investigate efficacy safety herbal formula ( KBMSI-2 ) treatment ED . Material Methods : Patients instructed take investigational product ( KBMSI-2 6g placebo ) twice day 8 week least 1 hour food intake . The primary efficacy variable change EF domain score IIEF questionnaire baseline . Secondary efficacy measure include change domain score IIEF baseline , change question 2 3 SEP2,3 , baseline .</brief_summary>
	<brief_title>The Efficacy Safety New Herbal Formula ( KBMSI-2 ) Treatment Erectile Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>Inclusion criterion follow : men history ED least 6 month accord National Institutes Health ( NIH ) Consensus Statement ( inability attain and/or maintain penile erection sufficient satisfactory sexual performance ) ; erectile function ( EF ) domain score International Index Erectile Function ( IIEF ) questionnaire â‰¤ 25 ; age range 19 40 year old ; patient require involved stable , monogamous relationship female sexual partner fail &gt; 50 % least four sexual attempt runin period . Exclusion criterion follow : Men follow condition exclude study : penile anatomical defect , spinal cord injury , radical prostatectomy , radical pelvic surgery ; primary diagnosis another sexual disorder ; uncontrolled DM ( HBA1C &gt; 12 % ) ; serum creatinine &gt; 2.5mg/dL ; major uncontrolled psychiatric disorder ; history major hematological , renal , hepatic abnormality ; recent ( within previous 6 month ) history cardiovascular disease , stroke myocardial infarction , cardiac failure , unstable angina , lifethreatening arrhythmia history alcoholism substance abuse . Patients take PDE5 inhibitor testosterone replacement therapy within 2 week exclude study . Concomitant use ED treatment forbidden .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>